Methocarbamol
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Methocarbamol
- Generic name
- METHOCARBAMOL
- Manufacturer
- Northwind Health Company, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- f31ccb09-7a9a-60af-e053-2995a90a6e97
- SPL ID
- 494e36ce-4cbb-e470-e063-6394a90a2955
- Version
- 2
- Effective date
- 2026-01-01
- Source export date
- 2026-09-28
- Source partition
- 4
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/c7ca0b7091cdaeab3f27713a6eef00adcf8fe722383633ddce61531b4c840544/drug-label-0004-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:25:51
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 090200 | derived:openfda.application_number |
| application number | ANDA090200 | openfda.application_number | |
| brand name | Methocarbamol | openfda.brand_name | |
| generic name | METHOCARBAMOL | openfda.generic_name | |
| manufacturer name | Northwind Health Company, LLC | openfda.manufacturer_name | |
| ndc | package | 51655-574-84 | openfda.package_ndc |
| ndc | package | 51655-574-52 | openfda.package_ndc |
| ndc | product | 51655-574 | openfda.product_ndc |
| ndc11 | package | 51655057484 | derived:openfda.package_ndc |
| ndc11 | package | 51655057452 | derived:openfda.package_ndc |
| rxcui | 197943 | openfda.rxcui | |
| spl id | 494e36ce-4cbb-e470-e063-6394a90a2955 | id | |
| spl set id | f31ccb09-7a9a-60af-e053-2995a90a6e97 | set_id | |
| unii | 125OD7737X | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS Since methocarbamol may possess a general CNS depressant effect, patients receiving methocarbamol tablets USP should be cautioned about combined effects with alcohol and other CNS depressants. Safe use of methocarbamol tablets USP has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol tablets USP should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see PRECAUTIONS , Pregnancy ). Use In Activities Requiring Mental Alertness Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Adverse reactions reported coincident with the administration of methocarbamol include: Body as a whole : Anaphylactic reaction, angioneurotic edema, fever, headache Cardiovascular system : Bradycardia, flushing, hypotension, syncope, thrombophlebitis Digestive system: Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting Hemic and lymphatic system: Leukopenia Immune system : Hypersensitivity reactions Nervous system: Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo Skin and special senses : Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticarial
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.